Skip to Content
Merck
CN

Key Documents

View All Documentation

SML2482

Ticagrelor

≥98% (HPLC), adensoine purinoceptor P2Y12 receptor antagonist, powder

Synonym(s):

Ticagrelor, (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5­(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol, (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C23H28F2N6O4S
CAS Number:
274693-27-5
Molecular Weight:
522.57
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
MFCD09954148
Assay:
≥98% (HPLC)
Form:
powder
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Ticagrelor, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -55 to -65°, c = 0.2 in methanol

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

FC1=C(F)C=C([C@]2([H])C[C@@]2([H])NC3=NC(SCCC)=NC4=C3N=NN4[C@]5([H])C[C@H](OCCO)[C@@H](O)[C@H]5O)C=C1

InChI

1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

InChI key

OEKWJQXRCDYSHL-FNOIDJSQSA-N

Gene Information

human ... P2RY12(64805)

General description

Ticagrelor (AZD6140) is a cyclopentyl-triazolopyrimidine.

Biochem/physiol Actions

Ticagrelor is an antithrombotic antiplatelet drug that acts by direct and reversible competitive inhibition of the adensoine purinoceptor P2Y12 receptor. It has clinical benefits in people affected with acute coronary syndrome. It might also play a beneficial role on endothelial function. Ticagrelor can prevent the uptake of adenosine by human erythrocytes and can promote the liberation of adenosine triphosphate (ATP) from human erythrocytes.

Still not finding the right product?

Explore all of our products under Ticagrelor

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000334118
0000531288
0000531288
0000334118
0000388592

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Athanasios Moulias et al.
Journal of cardiovascular pharmacology and therapeutics, 24(1), 11-17 (2018-07-12)
Ticagrelor is a P2Y12 receptor antagonist with proven clinical benefit in patients with acute coronary syndrome. Apart from its principal antiplatelet action, pleiotropic effects have been implicated in the clinical profile of ticagrelor, including a potentially beneficial impact on endothelial
Michał J Kubisa et al.
Therapeutics and clinical risk management, 14, 129-140 (2018-02-06)
Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS). A P2Y12 receptor antagonist, ticagrelor
José C Nicolau et al.
Expert opinion on pharmacotherapy, 19(9), 1013-1019 (2018-06-13)
Cardiovascular disease (CVD) is the main cause of death in the world. Coronary artery disease (CAD) is the most common form of CVD presentation, but the prevalence of peripheral artery disease (PAD) is increasing. Patients with polyvascular disease comprise a
View All Related Papers